← Back to Search

Statistical Learning for Epilepsy

N/A
Recruiting
Led By Taylor J Abel, MD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Normal hearing acuity in each ear (as determined by audiometric assessment)
Individuals 15-25 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during seeg-eeg recording sessions, up to 3 hours total
Awards & highlights
No Placebo-Only Group

Summary

This trial is exploring how the brain processes speech by looking at the activity in the temporal lobe. This area is responsible for mapping acoustic information to linguistic representation and is difficult to study non-invasively. This trial will help researchers understand how the brain responds to different aspects of speech and how this response changes in different listening contexts.

Who is the study for?
This trial is for individuals aged 15-25 with epilepsy who are undergoing sEEG in the supratemporal plane and have normal hearing, vision, cognitive, and speech-language skills. They must be fluent English speakers without a history of autism or ADHD.
What is being tested?
The study explores how the brain processes speech by examining responses to voice onset time (VOT) and fundamental frequency (F0) during routine clinical sEEG monitoring in patients with epilepsy.
What are the potential side effects?
Since this research involves non-invasive observation during a standard clinical procedure (sEEG), there are no additional side effects associated with the interventions being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My hearing is normal in both ears.
Select...
I am between 15 and 25 years old.
Select...
I am fluent in English.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during seeg-eeg recording sessions, up to 3 hours total
This trial's timeline: 3 weeks for screening, Varies for treatment, and during seeg-eeg recording sessions, up to 3 hours total for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Behavioral Impact of Change in Acoustic-Phonetic Dimensions
Behavioral Impact of Change in Listening Context
Supratemporal Neural Response to Change in Acoustic-Phonetic Dimensions
+1 more
Secondary study objectives
Neural Response of Non-Regions of Interest to Change in Acoustic-Dimension
Neural Response of Non-Regions of Interest to Change in Listening Context

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patient ParticipantsExperimental Treatment1 Intervention
This single-group study will recruit patients through the PI's clinical practice who are undergoing invasive neurophysiological monitoring (sEEG) with clinically necessary placement of electrodes in the supratemporal plane. All participants will complete the same behavioral response paradigms.

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,787 Previous Clinical Trials
16,359,328 Total Patients Enrolled
1 Trials studying Epilepsy
National Institutes of Health (NIH)NIH
2,811 Previous Clinical Trials
8,161,233 Total Patients Enrolled
7 Trials studying Epilepsy
514 Patients Enrolled for Epilepsy
Carnegie Mellon UniversityOTHER
77 Previous Clinical Trials
539,870 Total Patients Enrolled

Media Library

Dimension-Based Statistical Learning Clinical Trial Eligibility Overview. Trial Name: NCT05209386 — N/A
Epilepsy Research Study Groups: Patient Participants
Epilepsy Clinical Trial 2023: Dimension-Based Statistical Learning Highlights & Side Effects. Trial Name: NCT05209386 — N/A
Dimension-Based Statistical Learning 2023 Treatment Timeline for Medical Study. Trial Name: NCT05209386 — N/A
~0 spots leftby Dec 2024